108 related articles for article (PubMed ID: 11934915)
1. Subclinical type 1 diabetes.
Chowdhury TA; Lasker SS
J R Soc Med; 2002 Apr; 95(4):203-4. PubMed ID: 11934915
[No Abstract] [Full Text] [Related]
2. Repaglinide for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
[No Abstract] [Full Text] [Related]
3. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
Owens D
J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
[No Abstract] [Full Text] [Related]
4. Insulin secretagogues.
Kock M
J Assoc Physicians India; 1997; Suppl 1():48. PubMed ID: 11235637
[No Abstract] [Full Text] [Related]
5. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.
Meneilly GS
Diabetes Technol Ther; 2011 Jan; 13(1):63-5. PubMed ID: 21175273
[TBL] [Abstract][Full Text] [Related]
6. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
7. The importance of rapid insulin secretion: revisited.
Grodsky GM
Diabetes Technol Ther; 1999; 1(3):259-60. PubMed ID: 11475271
[No Abstract] [Full Text] [Related]
8. [Prandial glucose regulator for type 2 diabetic patients. Beta cells produce insulin according to need].
MMW Fortschr Med; 1999 Sep; 141(36):61. PubMed ID: 10904606
[No Abstract] [Full Text] [Related]
9. Current understanding regarding the role of repaglinide in post-prandial hyperglycemia.
Menon PS
J Assoc Physicians India; 2001 Jan; 49 Spec No():50-3. PubMed ID: 11235606
[No Abstract] [Full Text] [Related]
10. Repaglinide dose response? A clinician's viewpoint.
Schade DS
Diabetes Technol Ther; 1999; 1(3):257-8. PubMed ID: 11475270
[No Abstract] [Full Text] [Related]
11. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
12. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
de Luis DA; Aller R; Cuellar L; Terroba C; Ovalle H; Izaola O; Romero E
Diabetes Care; 2001 Oct; 24(10):1844-5. PubMed ID: 11574456
[No Abstract] [Full Text] [Related]
13. Repaglinide: a novel oral antidiabetic agent.
Nattrass M
Hosp Med; 2000 Feb; 61(2):112-5. PubMed ID: 10748789
[TBL] [Abstract][Full Text] [Related]
14. Continuous glucose monitoring: physiologic and pathophysiologic significance.
Ionescu-Tîrgovişte C; Guja C; Ioacără S; Dumitrescu D; Tomescu I
Rom J Intern Med; 2004; 42(2):381-93. PubMed ID: 15529628
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
Rizzo MR; Barbieri M; Grella R; Passariello N; Barone M; Paolisso G
Diabetes Metab; 2004 Feb; 30(1):81-9. PubMed ID: 15029102
[TBL] [Abstract][Full Text] [Related]
16. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
Moses R
Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
[TBL] [Abstract][Full Text] [Related]
17. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
[TBL] [Abstract][Full Text] [Related]
18. Improving management of type 2 diabetes mellitus: 4. Meglitinides.
Quillen DM; Kuritzky L; Samraj GP
Hosp Pract (1995); 1999 Dec; 34(13):38-40. PubMed ID: 10611897
[No Abstract] [Full Text] [Related]
19. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
[TBL] [Abstract][Full Text] [Related]
20. Postprandial hyperglycemia: are all sulfonylureas created equal?
Kapoor JR
Am J Cardiol; 2008 Feb; 101(4):554-5. PubMed ID: 18312779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
